Skip to main content
Clinical Trials/NCT05058781
NCT05058781RecruitingNot Applicable

Evaluation of Minipuberty in Infants Born With a Variation in Sexual Development

Centre Hospitalier Universitaire Vaudois1 site in 1 country100 target enrollmentStarted: January 1, 2017Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
100
Locations
1
Primary Endpoint
Hormonal changes in blood and in urine during minipuberty (LH, FSH, steroid profile, Testosterone, Estradiol (in girls), AMH, inhibin B)

Study Overview

Brief Summary

Disorders of sex development (DSD) occur in 1/3000 births and are defined by variation in aspect of external genital organs, e.g. cryptorchidism, hypospadias and micropenis in male infants and clitoral hypertrophy in female infants. Genetic, hormonal and environmental factors are implicated in DSD. Infants with congenital hypogonadism hypogonadotrope (CHH) can present with DSD. Evaluation of hormonal profile during minipuberty could be of great help to better characterize the etiology of DSD and CHH in particular. Our main objective is to study hormonal profile during the minipuberty of infants born with DSD or born from parents with CHH compared to controls.

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Prospective

Eligibility Criteria

Ages
— to 9 Months (Child)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • infants born with symptoms of DSD
  • infants born from parents with CHH

Exclusion Criteria

  • premature < 35 weeks of gestation
  • male infants with high scrotal cryptorchidism

Outcomes

Primary Outcomes

Hormonal changes in blood and in urine during minipuberty (LH, FSH, steroid profile, Testosterone, Estradiol (in girls), AMH, inhibin B)

Time Frame: at 2, 6 and 9 months of age (window for minipuberty)

Reproductive profile: LH and FSH (UI/L) steroid profile (nmol/L) Testosterone and Estradiol (nmol/L) AMH (ng/mL) inhibin B (pg/mL)

Secondary Outcomes

  • change in expression of genes involved in the NO pathway(at birth (if available), 2, 6 and 9 months of age)
  • quantification of Nitric Oxide metabolites during minipuberty(at 2, 6 and 9 months of age)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Nelly Pitteloud

Professor, Head od Endocrine department

Centre Hospitalier Universitaire Vaudois

Study Sites (1)

Loading locations...

Similar Trials